Defective and normal haematopoietic stem cells in paroxysmal nocturnal haemoglobinuria
- 1 July 1993
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 84 (3) , 504-514
- https://doi.org/10.1111/j.1365-2141.1993.tb03108.x
Abstract
Summary. The expression of decay‐accelerating factor (DAF or CD55) and CD59 during haematopoietic cell development in bone marrow aspirates of two patients with paroxysmal nocturnal haemoglobulinuria (PNH) was compared with that in normal bone marrow by five‐dimensional flow cytometry. In contrast to early uncommitted haematopoietic progenitor cells (CD34+, CD38‐) in normal bone marrow which uniformly express DAF and CD59, the majority of CD34+, CD38‐ cells in both patients' marrow exhibited the absence of the two proteins. In both specimens, however, subpopulations of CD34+, CD38‐ cells expressing DAF and CD59 were detectable, indicative of the presence of two lines of haematopoiesis, one abnormal and the other normal. Concurrent abnormal and normal haematopoietic development was further evident by the presence of subpopulations of DAF‐, CD59‐ and DAF+, CD59+ cells along the differentiation and maturation pathways of the myeloid (CD33+, CD15‐ → CD33+→++, CD15+), the erythroid (CD45dim, CD71dim→ CD45‐, CD71++), and the B‐lymphoid cell lineages (CD10++, CD20‐ → CD10‐, CD20++). While the majority of cells differentiating into and maturing along each cell lineage lacked DAF and CD59, the majority of mature B (CD20++, CD10‐) and T‐lymphocytes (CD3+) expressed both proteins suggestive of the presence of lymphocytes with a long life span which were generated from normal haematopoietic progenitors before the onset of the disease. The detection of distinct sets of CD34+, CD38‐ →+ progenitor cells which are DAF+, CD59+ or DAF‐, CD59‐ in marrow of PNH patients has relevance for the treatment of PNH. Cells with the phenotype CD34+, CD38‐, DAF+, CD59+ are capable of self renewal and represent potential candidates for autologous bone marrow transplantation following depletion of CD34+, CD38‐, DAF‐, CD59‐ cells.Keywords
This publication has 28 references indexed in Scilit:
- The control of homologous lysisImmunology Today, 1991
- H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complementCellular Immunology, 1990
- Increased light scattering resolution facilitates multidimensional flow cytometric analysisCytometry, 1990
- Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.Journal of Clinical Investigation, 1990
- CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.The Journal of Experimental Medicine, 1989
- Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.Journal of Clinical Investigation, 1989
- Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties.The Journal of Experimental Medicine, 1989
- Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipidBiochemistry, 1986
- Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.The Journal of Experimental Medicine, 1986
- Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.The Journal of Experimental Medicine, 1985